PBPeter B. Berger

Peter B. Berger

*This is an algorithmically generated author record based on publicly available information.

Peter B. Berger has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Adnan Kastrati

    DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance , Munich , Germany 3 Deutsches Herzzentrum München , Technische Universität München , Munich , Germany 4 I. Medizinische Klinik, Klinikum rechts der Isar , Technische Universität München , Munich , Germany

    1 shared publication
  • Alfred S. Casale

    Department of Cardiothoracic Surgery, Geisinger Medical Center, Danville, Pennsylvania

    1 shared publication
  • Charles Benoit

    Department of Cardiothoracic Surgery, Geisinger Medical Center, Danville, Pennsylvania

    1 shared publication
  • Dirk Sibbing

    Department of Cardiology , Ludwig-Maximilians-Universität München , Munich , Germany 2 DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance , Munich , Germany

    1 shared publication
  • Edward Woods

    Department of Cardiothoracic Surgery, Geisinger Medical Center, Danville, Pennsylvania

    1 shared publication
  • Eric S. Wagner

    Cardiovascular Center for Clinical Research, Geisinger Medical Center, Danville, Pennsylvania

    1 shared publication

Latest Publications

  • STEMI Care in Poland and the United States

    by Peter B. Berger, Molly Perini, Lance B. Becker

  • Open Access

    Pre-treatment with P2Y12inhibitors in ACS patients: who, when, why, and which agent?

    by Dirk Sibbing, Adnan Kastrati, Peter B. Berger

    Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay of treatment for acute coronary syndrome (ACS) patients, whether they undergo a percutaneous coronary intervention (PCI) or are managed medically. In recent years, the most appropriate timing for initiation and duration of P2Y12 receptor inhibition has been a focus of great interest. Many observational studies and a single prospective trial (CREDO) utilizing clopidogrel had focused on whether pre-treatment with clopidogrel, i.e. its administration upstream of coronary angiography and PCI, is beneficial. Although the rationale for pre-treatment is obvious, large-scale randomized trials supporting a pre-treatment strategy with clopidogrel or with the newer P2Y12 inhibitors prasugrel and ticagrelor did not exist. Proponents of a pre-treatment strategy had to rely on their best guess, on non-randomized studies, or on negative studies in which a trend for a benefit had been demonstrated. Recently, however, two randomized trials directly evaluated the value of pre-treatment—one in patients with a non-STE elevation myocardial infarction (NSTEMI)—the Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction (ACCOAST) trial, and a second trial evaluating the use of ticagrelor in ST-elevation myocardial infarction (STEMI) patients, the Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST-elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial. Neither of the two trials, however, answered all the questions clinicians have about pre-treatment. And given the recent approval of the intravenous and rapidly acting P2Y12 inhibitor cangrelor, the choice of who should receive treatment with a P2Y12 inhibitor, which one should be used, and when it should be administered, should be carefully re-evaluated for all patients. This clinical review aims at evaluating the available evidence regarding the value of pre-treatment with the now four available oral and intravenous P2Y12 inhibitors that can be administered to patients in whom coronary angiography followed by a possible PCI is planned.


  • Open Access

    Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?

    by Peter B. Berger, H. Lester Kirchner, Eric S. Wagner, Ibrahim Ismail‐Sayed, Salma Yahya, Charles Benoit, James C. Blankenship, Russell Carter, Alfred S. Casale, Sandy M. Green, et al.

    Objective: We sought to examine the relationship between preoperative platelet function and perioperative bleeding in patients undergoing CABG.Background: There are many ways to measure platelet aggregability. Little is known about their correlations with one another, or with bleeding.Methods: We prospectively studied 50 patients undergoing a first isolated off‐pump CABG. Thirty‐four were exposed to a thienopyridine prior to surgery; 16 were not. Preoperative platelet function was measured by VerifyNow®, TEG®, AggreGuide™, Plateletworks®, vasodilator‐stimulated phosphoprotein (VASP) phosphorylation, and light transmission aggregometry. Bleeding was assessed 2 ways: drop from pre‐ to nadir postoperative hematocrit, and chest tube drainage. Correlation coefficients were calculated using Spearman's rank‐order correlation.Results: Mean age was 62 years. Patient characteristics and surgical details were similar between the thienopyridine‐exposed and non‐exposed patients. The correlation coefficients between the 4 point‐of‐care platelet function measurements and hematocrit change ranged from −0.2274 to 0.2882. Only Plateletworks® correlated with drop in hematocrit (r = 0.2882, P = 0.0470). The correlation coefficients between each of the 4 point‐of‐care platelet function tests and the chest tube drainage were also poor, ranging from −0.3073 to 0.2272. Both AggreGuide™ (r = −0.3073, P = 0.0317) and VASP (r = −0.3187, P = 0.0272) were weakly but significantly correlated with chest tube drainage. The correlation among the 4 point‐of‐care platelet function measurements was poor, with coefficients ranging from −0.2504 to 0.1968.Conclusions: We observed little correlation among 4 platelet function tests, and between those assays and perioperative bleeding defined 2 different ways. Whether any of these assays should be used to guide decision making in individual patients is unclear. (J Interven Cardiol 2015;28:223–232)